Clinical Trial: N-3C01 Monotherapy and Combination With PD-(L)1 Inhibitors in Advanced Solid Tumors

U.S., June 11 -- ClinicalTrials.gov registry received information related to the study (NCT07639450) titled 'N-3C01 Monotherapy and Combination With PD-(L)1 Inhibitors in Advanced Solid Tumors' on May 18.

Brief Summary: This Phase I/II study evaluates the safety, tolerability, and efficacy of N-3C01 administered subcutaneously, both as monotherapy and in combination with a PD-(L)1 monoclonal antibody, in patients with advanced solid tumors. Phase I involves dose escalation for both monotherapy and combination therapy, while Phase II includes cohort expansion for the combination therapy.

Study Start Date: May 29

Study Type: INTERVENTIONAL

Condition: Advanced Malignant Solid Tumors

Intervention: DRUG: N-3C01(Q2W)

subcutaneous injectio...